NCT03223272View on ClinicalTrials.gov

Mechanisms of Refractory Hypertension (Reserpine)

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 23, 2015

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Refractory Hypertension
Interventions
DRUG

Reserpine

Open label reserpine 0.1 mg pill orally

Trial Locations (1)

35292

UAB, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT03223272 - Mechanisms of Refractory Hypertension (Reserpine) | Biotech Hunter | Biotech Hunter